Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Peking Union Medical College details research in cancer vaccines
October 14th, 2008
A report, 'Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine,' is newly published data in Cancer Letters. "Rituximab is a chimeric monoclonal antibody against CD20, and has been used to treat malignant tumors derived from B cell. We designed a tumor cell vaccine modified by Rituximab, and evaluated anti-tumor effect in human CD20 gene transfected mice tumor model in vivo, and in human CTLs induction by mixed lymphocyte tumor cell culture in vitro," researchers in Beijing, People's Republic of China report. "The results demonstrated that the Rituximab-coated tumor cell vaccine had a significant therapeutic effect against tumor pulmonary...
Source: Cancer Weekly (2008-10-14)
|
